NCT05510934 Shared Care Thyroid Cancer Follow-up Utilizing Thyroid Cancer Assessment Reminder System (TCARS) Study - A Pilot Study.
| NCT ID | NCT05510934 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nova Scotia Health Authority |
| Condition | Low Risk Differentiated Thyroid Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-09-30 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2022-09-30 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess the feasibility of a shared-care model for low-risk differentiated thyroid cancer (DTC) patients, primary care practitioners (PCPs) and the tertiary care center utilizing a digital health-based thyroid cancer assessment reminder system (TCARS) in Medable with an expedited referral to specialists for rapid assessment in case of a concern of recurrence.
Eligibility Criteria
Inclusion Criteria: Adult (\>18 years old) consenting patients being followed at the Halifax Interdisciplinary Thyroid Oncology Clinic (ITOC) meeting the following criteria: * AJCC stage 1 DTC with no radiological or biochemical evidence of thyroid cancer with undetectable high sensitivity serum thyroglobulin (hsTG \<0.06 mcg/L\*); * Anti-thyroglobulin antibody (anti-TG AB \<20 IU/ml\*); * Thyroid ultrasound scan \[USS\] negative for regional recurrence at least 24 months after most recent treatment; * AJCC stage 2 DTC with no radiological or biochemical evidence of cancer (undetectable hsTG and anti-TG AB and negative thyroid USS) at least 48 months after most recent treatment * Patient is comfortable with using the mobile or Medable application and has access to internet. Exclusion Criteria: Patient does not have a consented PCP.
Contact & Investigator
Syed A. Imran, Dr.
PRINCIPAL INVESTIGATOR
Nova Scotia Health
Frequently Asked Questions
Who can join the NCT05510934 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Low Risk Differentiated Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05510934 currently recruiting?
Yes, NCT05510934 is actively recruiting participants. Contact the research team at Ali.Imran@nshealth.ca for enrollment information.
Where is the NCT05510934 trial being conducted?
This trial is being conducted at Halifax, Canada.
Who is sponsoring the NCT05510934 clinical trial?
NCT05510934 is sponsored by Nova Scotia Health Authority. The principal investigator is Syed A. Imran, Dr. at Nova Scotia Health. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.